scholarly journals Robotic hand port assisted resection of liver and peritoneal metastases in patient with high-grade myxoid liposarcoma

HPB ◽  
2021 ◽  
Vol 23 ◽  
pp. S640
Author(s):  
K. Ginting ◽  
S. Allamaneni
Keyword(s):  
Myxoid Liposarcoma ◽  
Peritoneal Metastases ◽  
Robotic Hand ◽  
High Grade ◽  
Hand Port

scholarly journals Targeting progesterone signaling prevents metastatic ovarian cancer

2020 ◽  
Vol 117 (50) ◽  
pp. 31993-32004
Author(s):  
Olga Kim ◽  
Eun Young Park ◽  
Sun Young Kwon ◽  
Sojin Shin ◽  
Robert E. Emerson ◽  
...  
Keyword(s):  
Ovarian Cancer ◽  
Deleterious Mutation ◽  
Peritoneal Metastases ◽  
Cancer Development ◽  
Serous Carcinoma ◽  
Cancer Type ◽  
High Grade ◽  
Primary Tumors ◽  
High Risk Populations ◽  
Genetic Deletion

Effective cancer prevention requires the discovery and intervention of a factor critical to cancer development. Here we show that ovarian progesterone is a crucial endogenous factor inducing the development of primary tumors progressing to metastatic ovarian cancer in a mouse model of high-grade serous carcinoma (HGSC), the most common and deadliest ovarian cancer type. Blocking progesterone signaling by the pharmacologic inhibitor mifepristone or by genetic deletion of the progesterone receptor (PR) effectively suppressed HGSC development and its peritoneal metastases. Strikingly, mifepristone treatment profoundly improved mouse survival (∼18 human years). Hence, targeting progesterone/PR signaling could offer an effective chemopreventive strategy, particularly in high-risk populations of women carrying a deleterious mutation in the BRCA gene.

Prognostic value of the volume time index (VTI) ratio for patients with appendiceal cancer with peritoneal carcinomatosis treated by cytoreductive surgery and hyperthermic intraperitoneal chemotherapy (CRS/HIPEC).

2019 ◽  
Vol 37 (15_suppl) ◽  
pp. e15704-e15704
Author(s):  
Josh Karpes ◽  
Daniel Dotta ◽  
Oliver Fisher ◽  
Raphael Shamavonian ◽  
Nayef Alzahrani ◽  
...  
Keyword(s):  
Overall Survival ◽  
Prognostic Factor ◽  
Peritoneal Dissemination ◽  
Tumour Volume ◽  
Peritoneal Metastases ◽  
Low Grade ◽  
High Grade ◽  
Appendiceal Cancer ◽  
Appendix Cancer ◽  
Significant Difference

e15704 Background: Completeness of cytoreduction score (CC-score) and tumour volume (as expressed by the peritoneal cancer index (PCI)) have been demonstrated as important post-operative prognostic factors in those patients with appendix cancer with peritoneal metastases undergoing CRS/HIPEC. A previous analysis included a pre-operative factor and demonstrated the tumour marker to volume index (CA19-9/PCI) in patients who had low grade appendiceal cancer with peritoneal metastases was an independent prognostic factor for overall survival (OS). This analysis aims to evaluate VTI as a prognostic factor in low- and high-grade appendix neoplasms with peritoneal dissemination managed with CRS/HIPEC. Methods: A retrospective cohort study of all patients diagnosed with appendiceal cancer with peritoneal dissemination managed with CRS/IPC from 1996 to 2017 was performed by analysing the survival effect of the ratio of tumour volume to the time between initial tumour resection and CRS/HIPEC. VTI was stratified into low versus high groups, and tumour grade was divided into low grade: diffuse peritoneal adenomucinosis (DPAM); and high grade: peritoneal mucinous carcinomatosis (PMCA). Results: Two hundred and sixty-four patients were included. For both DPAM and PMCA, there was no statistically significant difference in overall survival between patients with a low versus high VTI. For both low and high VTI in DPAM, the median survival was not reached, p= 0.586. For PMCA, those with a low VTI had an overall survival of 63 months (95%CI 48-NR), versus those with a high VTI 69 months (95%CI 45-NR), p= 0.97. There was no statistically significant difference in the median recurrence free survival (RFS) between low and high VTI for both DPAM and PMCA. Conclusions: The volume to time ratio for appendix cancer with peritoneal dissemination was not an independent prognostic indicator for overall survival in patients undergoing CRS/HIPEC, suggesting that this index is not a valuable pre-operative planning tool.

Predictors of survival in patients with high-grade peritoneal metastases undergoing cytoreductive surgery and hyperthermic intraperitoneal chemotherapy

Surgery ◽  
2012 ◽  
Vol 152 (4) ◽  
pp. 617-625 ◽  
Author(s):  
Heather L. Van Sweringen ◽  
Dennis J. Hanseman ◽  
Syed A. Ahmad ◽  
Michael J. Edwards ◽  
Jeffrey J. Sussman
Keyword(s):  
Intraperitoneal Chemotherapy ◽  
Cytoreductive Surgery ◽  
Hyperthermic Intraperitoneal Chemotherapy ◽  
Peritoneal Metastases ◽  
High Grade

High-Grade Myxoid Liposarcoma (Round Cell Variant) in a Dog

2016 ◽  
Vol 155 (4) ◽  
pp. 305-309 ◽  
Author(s):  
Q.D. Plumlee ◽  
A.M. Hernandez ◽  
S.D. Clark ◽  
A. Bascuñán ◽  
J. Davidson ◽  
...  
Keyword(s):  
Myxoid Liposarcoma ◽  
High Grade ◽  
Round Cell ◽  
Cell Variant

MRI characteristics associated with high-grade myxoid liposarcoma

2017 ◽  
Vol 72 (7) ◽  
pp. 613.e1-613.e6 ◽  
Author(s):  
L.H. Gimber ◽  
E.A. Montgomery ◽  
C.D. Morris ◽  
E.A. Krupinski ◽  
L.M. Fayad
Keyword(s):  
Myxoid Liposarcoma ◽  
High Grade ◽  
Mri Characteristics

scholarly journals Microscopic Peritoneal Residual Disease after Complete Macroscopic Cytoreductive Surgery for Advanced High Grade Serous Ovarian Cancer

2020 ◽  
Vol 10 (1) ◽  
pp. 41
Author(s):  
Henri Azaïs ◽  
Anne-Sophie Vignion-Dewalle ◽  
Marine Carrier ◽  
Jeremy Augustin ◽  
Elisabeth Da Maïa ◽  
...  
Keyword(s):  
Ovarian Cancer ◽  
Cytoreductive Surgery ◽  
Systemic Chemotherapy ◽  
Residual Disease ◽  
Peritoneal Metastases ◽  
High Grade ◽  
Serous Ovarian Cancer ◽  
Conventional Surgery ◽  
Ovarian Cancers ◽  
A Prospective Study

Background: Epithelial ovarian cancers (EOC) are usually diagnosed at an advanced stage and managed by complete macroscopic cytoreductive surgery (CRS) and systemic chemotherapy. Peritoneal recurrence occurs in 60% of patients and may be due to microscopic peritoneal metastases (mPM) which are neither eradicated by surgery nor controlled by systemic chemotherapy. The aim of this study was to assess and quantify the prevalence of residual mPM after complete macroscopic CRS in patients with advanced high-grade serous ovarian cancer (HGSOC). Methods: A prospective study conducted between 1 June 2018 and 10 July 2019 in a single referent center accredited by the European Society of Gynecological Oncology for advanced EOC management. Consecutive patients presenting with advanced HGSOC and eligible for complete macroscopic CRS were included. Up to 13 peritoneal biopsies were taken from macroscopically healthy peritoneum at the end of CRS and examined for the presence of mPM. A mathematical model was designed to determine the probability of presenting at least one mPM after CRS. Results: 26 patients were included and 26.9% presented mPM. There were no differences in characteristics between patients with or without identified mPM. After mathematical analysis, the probability that mPM remained after complete macroscopic CRS in patients with EOC was 98.14%. Conclusion: Microscopic PM is systematically present after complete macroscopic CRS for EOC and could be a relevant therapeutic target. Adjuvant locoregional strategies to conventional surgery may improve survival by achieving microscopic CRS.

Nuclear expression of DDIT3 distinguishes high-grade myxoid liposarcoma from other round cell sarcomas

2021 ◽  
Author(s):  
Esther Baranov ◽  
Margaret A. Black ◽  
Christopher D. M. Fletcher ◽  
Gregory W. Charville ◽  
Jason L. Hornick
Keyword(s):  
Myxoid Liposarcoma ◽  
High Grade ◽  
Round Cell ◽  
Nuclear Expression
Sign in / Sign up

Export Citation Format

Share Document